What's New


July 21, 2016 - CitizenVox: An Important Remedy for Pharma's Exorbitant Pricing

July 20, 2016 - Letter from 56 Non-profit Organizations and Academic Experts to Secretary Kerry Regarding State Department Pressure Against Access to Medicines Efforts

July 20, 2016 - Public Health, Human Rights and Faith Organizations Question State Department Pressure Against Global Access to Medicines Initiatives

July 15, 2016 - Huffington Post: Taxpayers Funded A Lifesaving Drug And Guess What Happened Next (authored by Sen. Bernie Sanders)

July 13, 2016 - CitizenVox: Pharma (contribution) Addicts in Congress

July 8, 2016 - Public Citizen letter in U.S. News and World Report: An Overdue Fix for Medicare

For older news, visit the Access to Medicines news archive

The Medicines Patent Pool

In December 2009, UNITAID created the Medicines Patent Pool (MPP) as a separate entity to focus on increasing access to HIV medicines in developing countries. The Pool’s objective is to facilitate licensing agreements with patent holders and generic pharmaceutical manufacturers. Unlike state-based compulsory licenses or patent oppositions, MPP licenses can reach many countries at once, potentially changing the global access picture for a given drug.

Public Citizen sees the success of the MPP as an invaluable element in our fight to expand access to medicines. But for the Medicines Patent Pool to truly work, those of us in the global health community must continue to press for conditions which allow it to succeed. The MPP has the potential to be a game-changer for global health which contributes to saving millions of lives, but it can’t do it alone.



May 15, 2014 - Boehringer Ingelheim's response to Public Citizen's letter regarding the Medicines Patent Pool

April 25, 2014 - Novartis' response to Public Citizen's letter regarding the Medicines Patent Pool

April 23, 2014 - Johnson & Johnson's response to Public Citizen's letter regarding the Medicines Patent Pool

April 8, 2014 - Public Citizen letters to AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, F. Hoffman-La Roche, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Shionogi regarding the latest licensing agreement between ViiV Healthcare and the Medicines Patent Pool

April 1, 2014 - Medicines Patent Pool-ViiV Healthcare Licensing Agreement Statement of Peter Maybarduk, Global Access to Medicines Program Director

December 12, 2013 - Press Release: Medicines Patent Pool Reaches Licensing Deal with BMS to Expand Access to AIDS Drug

April 23, 2013 - Johnson & Johnson response to Public Citizen letter on the Medicines Patent Pool

April 22, 2013 - Bristol-Myers Squibb response to Public Citizen letter on the Medicines Patent Pool

April 2, 2013 - Public Citizen letters to Abbott Laboratories, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck & Co. and Pfizer regarding the ViiV Healthcare and Medicines Patent Pool Agreement

February 28, 2013 - Press Release: Medicines Patent Pool Reaches Licensing Deal for GSK Patents to Expand Access to Medicines for Children with HIV

December 22, 2011 - A brief history of Johnson & Johnson's refusal to negotiate with the Medicines Patent Pool

December 15, 2011 - Johnson & Johnson response to Public Citizen letter on the Medicines Patent Pool

December 10, 2011 - Public Citizen Brief on the Medicines Patent Pool

December 7, 2011 - Public Citizen letter to Tibotec/Johnson & Johnson urging them to negotiate licensing with the Medicines Patent Pool

Back to Access to Medicines Home Page

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.